Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer
oleh: Pietro Lapidari, Arnauld Gbenou, Julie Havas, Elise Martin, Barbara Pistilli, Anne-Laure Martin, Sibille Everhard, Charles Coutant, Paul Cottu, Anne Lesur, Florence Lerebours, Olivier Tredan, Laurence Vanlemmens, Christelle Jouannaud, Christelle Levy, Olivier Rigal, Marion Fournier, Fabrice Andre, Ines Vaz-Luis, Antonio Di Meglio
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2021-06-01 |
Deskripsi
We assessed long-term associations of Granulocyte-Colony Stimulating Factors (G-CSF) use with patient-reported outcomes (PROs) and hematologic toxicity among chemotherapy-treated, early-stage breast cancer patients in CANTO (NCT01993498).Among 2920 patients longitudinally followed-up until year-4 after diagnosis, 49% used G-CSF. In multivariable-adjusted mixed-models, EORTC QLQ-C30 pain and summary score were not substantially different between groups (overall adjusted mean difference, use vs no-use [95%CI]: +1.27 [-0.33 to +2.87] and −1.01 [-1.98 to −0.04], respectively). PROs were slightly worse at year-4 among patients receiving G-CSF, although differences were of trivial clinical significance. No major differences were observed in leukocyte or platelet count over time.